Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 376

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

One year follow-up of the multi-centre European PARTNER transcatheter heart valve study

Open access
Lefevre, T., Kappetein, A. P., Wolner, E., Nataf, P., Thomas, M., Schachinger, V., De Bruyne, B., Eltchaninoff, H., Thielmann, M., Himbert, D., Romano, M., Serruys, P., Wimmer-Greinecker, G., on behalf of the PARTNER EU Investigator Group·2011·European Heart Journal

Abstract

BACKGROUND: Transcatheter aortic valve implantation (TAVI) has emerged as a new therapeutic option in high-risk patients with severe aortic stenosis. AIMS: PARTNER EU is the first study to evaluate prospectively the procedural and mid-term outcomes of transfemoral (TF) or transapical (TA) implantation of the Edwards SAPIEN® valve involving a multi-disciplinary approach. METHODS AND RESULTS: Primary safety endpoints were 30 days and 6 months mortality. Primary efficacy endpoints were haemodynamic and functional improvement at 12 months. One hundred and thirty patients (61 TF, 69 TA), aged 82.1 ± 5.5 years were included. TA patients had higher logistic EuroSCORE (33.8 vs. 25.7%, P = 0.0005) and more peripheral disease (49.3 vs. 16.4%, P< 0.0001). Procedures were aborted in four TA (5.8%) and six TF cases (9.8%). Valve implantation was successful in the remaining patients in 95.4 and 96.4%, respectively. Thirty days and 6 months survival were 81.2 and 58.0% (TA) and 91.8 and 90.2% (TF). In both groups, mean aortic gradient decreased from 46.9 ± 18.1 to 10.9 ± 5.4 mmHg 6 months post-TAVI. In total, 78.1 and 84.8% of patients experienced significant improvement in New York Heart Association (NYHA) class, whereas 73.9 and 72.7% had improved Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in TA and TF cohorts, respectively. CONCLUSION: This first team-based multi-centre European TAVI registry shows promising results in high-risk patients treated by TF or TA delivery. Survival rates differ significantly between TF and TA groups and probably reflect the higher risk profile of the TA cohort. Optimal patient screening, approach selection, and device refinement may improve outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehq427

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 376

Metadata

Authors
Lefevre, T., Kappetein, A. P., Wolner, E., Nataf, P., Thomas, M., Schachinger, V., De Bruyne, B., Eltchaninoff, H., Thielmann, M., Himbert, D., Romano, M., Serruys, P., Wimmer-Greinecker, G., & on behalf of the PARTNER EU Investigator Group
Venue
European Heart Journal
Published
2010-11-12
Volume
32
Issue
2
Pages
148-157
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2069784595
Cited by
376
References
31
FWCI
39.24
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: One year follow-up of the multi-centre European PARTNER transcatheter heart valve study. https://app.cochat.ai/papers/10.1093/eurheartj/ehq427
The paper
Lefevre, T., Kappetein, A. P., Wolner, E., Nataf, P., Thomas, M., Schachinger, V., De Bruyne, B., Eltchaninoff, H., Thielmann, M., Himbert, D., Romano, M., Serruys, P., Wimmer-Greinecker, G., & on behalf of the PARTNER EU Investigator Group. (2011). One year follow-up of the multi-centre European PARTNER transcatheter heart valve study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehq427

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.